POXEL : Non-Alcoholic Steatohepatitis (NASH) Pipeline Analysis

darkcoco

17 avr. 2024 •10:17

En mars 2023, les résultats positifs de DESTINY-1 (Deuterium-stabilisized R-pioglitazone [PXL065] Efficacy and Safety Trial In NASH), un essai de phase 2 de dosage de 36 semaines, ont été publiés dans le Journal of Hepatology, selon POXEL. SA. Le PXL065 est un tout nouveau stéréoisomère R de pioglitazone exclusif avec une activité PPAR plus faible mais toujours les mêmes effets de pioglitazone non génomiques.

Some of the key companies in the Non-Alcoholic Steatohepatitis Therapeutics Market include:
Key companies developing therapies for Non-Alcoholic Steatohepatitis are - Madrigal Pharmaceuticals, Intercept Pharmaceuticals, Cirius Therapeutics, Novo Nordisk, Inventiva, Galmed Pharmaceuticals, AstraZeneca, Galectin Therapeutics, Viking Therapeutics, Eli Lilly and Company, Terns Pharmaceuticals, Sinew Pharma, 89bio, Inc., Enanta Pharmaceuticals, Inc, Eccogene, Novartis Pharmaceuticals, Poxel SA, AngioLab, Pfizer, Arrowhead Pharma, LG Chem, Redx Pharma, Lipocine, Inc., CytoDyn, Inc., Alnylam Pharmaceuticals, Inc., Chemomab Therapeutics, NuSirt Biopharma, HK inno. N, Aligos Therapeutics, Altimmune, Inc., Kowa Pharmaceutical, Ionis Pharmaceuticals, NorthSea Therapeutics, Rivus Pharmaceuticals, Hanmi Pharmaceutical, Hepagene Therapeutics, HighTide Biopharma, and others.